首页> 美国卫生研究院文献>Thoracic Cancer >Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma

【2h】

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma

机译：卡铂培美曲塞治疗作为中国晚期肺腺癌一线治疗药物的计算方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveThis study aims to explore the application of actual carboplatin in carboplatin plus pemetrexed regimen as first‐line treatment for advanced lung adenocarcinoma, and to determine the recommended dose of carboplatin for Chinese populations.

机译：目的本研究旨在探讨实际卡铂在卡铂加培美曲塞方案中作为晚期肺腺癌的一线治疗的应用，并确定卡铂在中国人群中的推荐剂量。

著录项

期刊名称 Thoracic Cancer
作者
Yixiang Zhu; Puyuan Xing; Shouzheng Wang; Di Ma; Yuxin Mu; Xue Li; Ziyi Xu; Junling Li;
展开▼
作者单位

展开▼
年(卷),期 2018(9),3
年度 2018
页码 400–407
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Advanced area under the curve carboplatin–pemetrexed lung adenocarcinoma;

机译：晚期;曲线下面积;卡铂培美曲塞;肺腺癌;

相似文献

外文文献
中文文献
专利

1. Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma [J] . Yixiang Zhu, Puyuan Xing, Shouzheng Wang, Thoracic cancer. . 2018,第3期

机译：卡铂培美曲塞治疗作为中国晚期肺腺癌患者一线治疗的计算卡铂剂量的评估
2. P2.01-025 Evaluation of Calculating Carboplatin Dosage in Carboplatin–Pemetrexed Therapy in Chinese Patients with Advanced NSCLC [J] . Y. Zhu, P. Xing, J. Li Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：P2.01-025评价Carboplatin-Pemetrexed治疗中Carboplatin剂量在中国高级NSCLC患者中的疗效
3. Evaluation of a method for calculating carboplatin dosage in DeVIC +/- R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma [J] . Tomono Ayana, Ito Kaori, Hayashi Takahiro, Cancer chemotherapy and pharmacology. . 2016,第2期

机译：评价复发性或难治性非霍奇金淋巴瘤患者用DeVIC +/- R治疗（地塞米松，依托泊苷，异环磷酰胺和卡铂联合或不联合利妥昔单抗）作为挽救治疗的计算卡铂剂量的方法
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone etoposide ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma [O] . Ayana Tomono, Kaori Ito, Takahiro Hayashi, -1

机译：评价DeVIC±R治疗（地塞米松依托泊苷异环磷酰胺和卡铂联合或不联合利妥昔单抗的联合治疗）中计算卡铂剂量作为挽救治疗的复发或难治性非霍奇金淋巴瘤患者
7. Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma [O] . 2016

机译：评价DeVIC±R治疗（地塞米松，依托泊苷，异环磷酰胺和卡铂联合或不联合利妥昔单抗的联合治疗）中计算卡铂剂量作为挽救治疗的复发或难治性非霍奇金淋巴瘤患者

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma

摘要

著录项

相似文献

相关主题

期刊订阅